Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilar User Fee Negotiations Hit Snag With GPhA Gambit For Lower Fees

Executive Summary

The Generic Pharmaceutical Association is balking at continuing to negotiate the design of a biosimilar user fee program that is independent of other user fees and has its own baseline appropriations trigger.

You may also be interested in...

Biosimilar Product Development Meetings With FDA To Be Flexible Under User Fee Program

Agency says pre-marketing application meetings will not be mandatory; program independence issue also appears resolved.

Burr Warns User Fee Renewal Could Be Difficult Without Performance Measure Improvements

Senator tells FDA Commissioner Hamburg that time to market is important metric during hearing dominated by questions about medical device review.

Biosimilar Product Development Fee Should Be Temporary, Trade Groups Say

Brand and generic drug trade associations disagree with FDA’s proposal to have biosimilar sponsors pay a product development fee before even submitting a marketing application.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts